ASCO 2019

ASCO 2019 Videos

Talazoparib in Advanced HER2-Negative Breast Cancer and Other Solid Tumors Lacking BRCA1/2 Mutations

Elderly Patients With Breast Cancer and CVD Risk Factors Found More Likely to Visit ER

Neratinib Improved PFS Compared With Lapatinib

EGFR-Mutant mNSCLC: Outcomes of Gefitinib + Pemetrexed-Carboplatin Chemotherapy

Pazopanib Found Not Beneficial Following Metastasectomy

Adjuvant Whole-Brain Radiotherapy Not Recommended for Melanoma Brain Metastases

Neoadjuvant Therapy Tied to High Pathological Response Rates

Heparin Derivative CX-01 May Boost Standard AML Induction

Sequential Exposure to FOLFOXIRI Plus Bevacizumab Shows Benefit

Promising Early Results for Preoperative Atezolizumab

ASCT Reduced the Risk of Early Relapse for Some Patients

BRAF and MEK Inhibitors Deemed Superior to Anti–PD-1

Novel Metric Sheds Light on When Adverse Events May Occur

Results of Enfortumab Vedotin Monotherapy for Urothelial Cancer

Randomized Phase III Trial of Lenalidomide vs. Observation Alone

Association of PBAF Complex Mutations With Survival

Gilteritinib Superior to Salvage Chemo

Adjuvant Ipilimumab Determined to Increase Overall Survival

Update at 9 Years of the GETUG-AFU 16 Phase III Randomized Trial

Pembrolizumab Improves Survival in NSCLC

ASCO 2019 Breast Cancer In-Depth

ASCO 2019 Complete Coverage

Researchers Find Clues as to How Implants Cause Breast Anaplastic Large Cell Lymphoma (ALCL)

Prospective Evidence Links Textured Breast Implants to Rare Lymphoma

The risk of breast implant-associated anaplastic large cell lymphoma may be higher than previously reported for women who receive textured implants, according to researchers.

Patients with breast cancer report financial barriers to quality care and provide suggestions for alleviating the economic burdens of the disease.

Breastfeeding Duration May Influence Markers of Inflammation and Proliferation in Breast Tissue of Healthy Parous Women

Morphologic features were examined to identify markers of inflammation, and proliferation index was assessed using Ki67 immunostaining.

For Patients With Advanced Non-Small Cell Lung Cancer (NSCLC), Dacomitinib Not Superior to Erlotinib

Efficacy of Maintenance Therapy After Induction Therapy in Patients With Nonsquamous NSCLC and Wild-Type EGFR

In this patient subset, BEV+PEM maintenance therapy after CAR+PEM+BEV induction therapy “could have survival benefits.”

With newer treatments, alternatives to dasatinib exist, if needed.

EGFR-Mutant mNSCLC: Outcomes of Gefitinib + Pemetrexed-Carboplatin Chemotherapy Versus Gefitinib Alone

Adding pemetrexed-carboplatin chemotherapy to gefitinib significantly prolonged PFS and OS but also increased toxicity.

RELAY Phase 3: Efficacy of the Addition of Ramucirumab to Erlotinib in EGFR-Mutant Metastatic NSCLC

RELAY is a multicenter, double-blind, randomized clinical trial that enrolledin patients who had no prior treatment for 1L epidermal growth factor receptor (EGFR)-mutant metastatic non−small cell lung cancer.

Women who survive breast cancer may have a higher-than-average risk of developing thyroid cancer in

Pazopanib Found Not Beneficial Following Metastasectomy in Metastatic RCC

The data suggest that OS may actually be worse for patients receiving pazopanib following surgery for metastatic RCC.

Close to 60% of all patients with VHL will develop RCC or renal cysts.

Combination of ICIs and Cytoreductive Surgery in Metastatic RCC Appears Promising

The expression of interferon-related genes in tumor specimens was associated with response to neoadjuvant immune checkpoint inhibitor-based therapy.

SN-MMR was strongly associated with OS, melanoma-specific survival, and DFS among patients with a po

Early MRD Status After CAR-T Administration Predicted PFS, OS

An analysis of patients in the ZUMA-1 trial found that day 28 minimal residual disease levels could identify patients at risk for early progression.

Preventive therapy for ER-negative breast cancer

Adding Apalutamide to ADT Prolongs Survival in mCSPC

In a study of men with metastatic castration-sensitive prostate cancer, apalutamide plus androgen deprivation therapy (ADT) decreased the risk of death by 33% compared with placebo plus ADT.

of onabotulinumtoxin A is a safe and effective treatment for oab

Earlier Pembrolizumab Use May Be Beneficial in mUC

In a phase 2 study, patients with metastatic urothelial carcinoma who had stable disease on first-line platinum-based chemotherapy experienced a delay in disease progression when switched to pembolizumab.

PET/CT Imaging for Recurrent PCa Detection More Accurate With PSMA

In a head-to-head comparative study involving PCa patients with early biochemical recurrence following radical surgery, PSMA PET/CT had significantly higher cancer detection rates than fluciclovine PET/CT.

Lymphoseek Expands the Field for Sentinel Lymph Node Detection

More Advanced PCa Diagnoses Followed USPSTF Screening Recommendations

Nodal and metastatic prostate cancer at diagnosis increased after 2008, when the USPSTF recommended against PSA screening for men aged 75 or older, and again when it expanded the recommendation for all men.

Better collaboration between community and academic cancer centers could benefit patients.

Nonrelapse Mortality After CAR-T Therapy Remains High

“Nonrelapse mortality needs to be defined prospectively for all ongoing CAR-T studies,” said the researchers.

Pembrolizumab may be an effective treatment for patients with a rare subtype of diffuse large B-cell

Early Study of PI3K Inhibitor Yields High Response Rate in R/R Follicular Lymphoma

Additional research is needed on the best dose schedule for the drug.

This fact sheet discusses the importance of palliative care as it pertains to cancer survivorship.

Value Frameworks Back Checkpoint Inhibitor Approvals in Palliative Setting

Frameworks used to make prescribing decisions on checkpoint inhibitors may need to be refined for adjuvant trials.

Adjuvant Whole-Brain Radiotherapy Not Recommended for Melanoma Brain Metastases

Secondary end points were not significantly different between the 2 groups, including overall survival.

Circulating tumor DNA conveyed prognosis among patients with high-risk stage III melanoma, reinforcing the need to include this measure in clinical trial design.

How to Treat Melanoma After Checkpoint Inhibitors Fail

The combination of ipilimumab and nivolumab resulted in a higher rate of objective remissions compared with ipilimumab alone.

A Closer Look at Two CommonTypes of Skin Cancer

Adjuvant Ipilimumab Determined to Increase Overall Survival in High-Risk Melanoma

Adjuvant ipilimumab may improve overall survival in patients with resected high-risk melanoma.

Novel targets in the treatment of melanoma was a hot topic of discussion during the 2018 American So

Neoadjuvant Therapy in Melanoma Tied to High Pathological Response Rates

Researchers concluded that the ability to achieve pCR correlated to improved recurrence-free survival in melanoma.

Patients younger than 50 years with NSCLC were more likely to have a targetable genomic alteration.

Venetoclax Plus Obinutuzumab Prevails as First-Line Combo in CLL

Patients with chronic lymphocytic leukemia who received venetoclax plus obinutuzumab had better survival outcomes compared with chemoimmunotherapy.

Next post in ASCO 2019

ASCO 2019

ASCO 2019 Videos

ASCO 2019 Complete Coverage

Want to read more?